bioMérieux – First-Half 2015 Results

• Strong growth in business
  • €933 million in sales
  • Up 19.5% as reported
  • Up 8.1% like-for-like
• Sharp 34% improvement in contributive operating income before non-recurring items lifted by strong business momentum, the disciplined management of operating expenses and the positive currency effect
• Sustained successful performance by FilmArray®
• 510(k) FDA clearance of VIDAS® 3
• Execution of the industrial investment plan
• Confirmation of the 2015 financial objectives

Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux delivered a solid performance in the first half of 2015, attesting to its effective positioning as a specialist in the in vitro diagnosis of infectious diseases. The strong dynamic observed during the past 6 months reflects our broad geographic footprint and our diversified portfolio of solutions, which was recently enhanced with the acquisition of BioFire in molecular biology. Against this backdrop, and despite the economic instability, we are confident in our ability to reach our 2015 objectives."

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 28 under the chairmanship of Jean-Luc Belingard and approved the consolidated financial statements for the six months ended June 30, 2015. The Statutory Auditors had performed a review of the financial statements.